Thanks pinch2020! nice finding.
So Novartis got whammy within 2 months: The US$2.9b acquired myelofibrosis drug Pelabresib halted in late October due to safety issue, and now the UCB's partnered Parkinson's asset fails phase 2 this week.
presumably Syntara's 5505 and 4782 are the perfect fits of these 2 holes in Novartis's pipeline. would be great If Gary can use his 8 years experience and connections in Novartis to bridge a deal between the 2 companies.
Just my speculation...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $79.62M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25013 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 6900 | 1 |
View Market Depth
| Last trade - 09.01am 23/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |
Day chart unavailable